Advanced search
Publication Cover
OncoImmunology Volume 1, 2012 - Issue 9
Submit an article Journal homepage
501
Views
11
CrossRef citations to date
0
Altmetric
Author's View

Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?

Yann Godet INSERM U1098; Unité Mixte de Recherche; Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté; Besançon, France; Université de Franche-Comté; Besançon, France
,
Magalie Dosset INSERM U1098; Unité Mixte de Recherche; Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté; Besançon, France; Université de Franche-Comté; Besançon, France
,
Christophe Borg INSERM U1098; Unité Mixte de Recherche; Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté; Besançon, France; Université de Franche-Comté; Besançon, France; CHRU de Besançon, Service d’Oncologie; Besançon, France
&
Olivier Adotevi INSERM U1098; Unité Mixte de Recherche; Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté; Besançon, France; Université de Franche-Comté; Besançon, France; CHRU de Besançon, Service d’Oncologie; Besançon, FranceCorrespondence[email protected]
Pages 1617-1619 | Published online: 06 Dec 2012

References

  • Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565 - 70; http://dx.doi.org/10.1126/science.1203486; PMID: 21436444
  • Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008; 222:129 - 44; http://dx.doi.org/10.1111/j.1600-065X.2008.00616.x; PMID: 18363998
  • Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298 - 306; http://dx.doi.org/10.1038/nrc3245; PMID: 22419253
  • Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151 - 60; http://dx.doi.org/10.1038/nrclinonc.2010.223; PMID: 21364688
  • Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res 2012; 18:2943 - 53; http://dx.doi.org/10.1158/1078-0432.CCR-11-3185; PMID: 22407833
  • Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59 - 73; http://dx.doi.org/10.1038/nri2216; PMID: 18097448
  • Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012; 30:1835 - 41; http://dx.doi.org/10.1200/JCO.2011.40.2271; PMID: 22529253
  • Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 2008; 111:5342 - 9; http://dx.doi.org/10.1182/blood-2007-12-128397; PMID: 18326818
  • Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 2012; 18:2326 - 35; http://dx.doi.org/10.1158/1078-0432.CCR-11-2515; PMID: 22355009
  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443 - 54; http://dx.doi.org/10.1056/NEJMoa1200690; PMID: 22658127

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.